{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:07:25Z","timestamp":1779188845345,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cancer and Leukemia Group B (CALGB) 10403 is a pediatric-inspired treatment protocol for adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients. During Course V maintenance, patients receive mercaptopurine (6MP) and oral methotrexate (MTX), which require frequent laboratory monitoring and dose adjustments. The purpose of this study was to characterize the impact of pharmacist intervention on the safe implementation of Course V.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective chart review included AYA patients with B- or T-cell ALL who initiated treatment with CALGB 10403 at UNCMC between April 2014 and April 2024. The primary endpoint was the rate of pharmacist-driven 6MP and MTX holds per protocol during Course V. The key secondary endpoint was the rate of pharmacist-driven 6MP and MTX dose adjustments during Course V.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All 18 patients required chemotherapy dose adjustments. Pharmacists led 6MP and MTX dose interruptions in 25 of 35 (71.4%) instances and dose modifications in 85 of the 140 (60.7%) instances. With the addition of a second pharmacist in the leukemia clinic, the monthly rate of pharmacist-led dose holds and modifications for 6MP and MTX increased by over four-fold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacists played a significant role in the safe administration of 6MP and MTX, particularly with the addition of a second clinic pharmacist. This study demonstrates the value of pharmacist involvement in optimizing patient safety during treatment of ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261421898","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:57:27Z","timestamp":1773226647000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing pharmacist impact in maintenance therapy for adolescent and young adults with acute lymphoblastic leukemia treated with CALGB 10403 protocol"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9907-9234","authenticated-orcid":false,"given":"Cami","family":"Andreini","sequence":"first","affiliation":[{"name":"University of North Carolina Medical Center"},{"name":"Duke University Health, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lam","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"},{"name":"Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Dennison","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Auten","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn M","family":"Buhlinger","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"},{"name":"AbbVie Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M","family":"Clark","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"},{"name":"McKesson Specialty Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-6676","authenticated-orcid":false,"given":"Benyam","family":"Muluneh","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison B","family":"Carroll","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"},{"name":"The University of Kansas Cancer Center, Westwood, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Klos","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"University of North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailey","family":"Hirata","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-0902","authenticated-orcid":false,"given":"Bianka","family":"Patel","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"e_1_3_3_3_2","volume-title":"Long-term follow-up of an intensive pediatric regimen for adolescents\/young adults (AYA) with acute lymphoblastic leukemia (ALL): 10-year survival following CALGB 10403 (Alliance)EHA2025 congress","author":"Stock W","unstructured":"Stock W, Yin J, Liedtke M, et al. Long-term follow-up of an intensive pediatric regimen for adolescents\/young adults (AYA) with acute lymphoblastic leukemia (ALL): 10-year survival following CALGB 10403 (Alliance). In: EHA2025 congress, Milan, Italy, 12\u201315 June 2025. Abstract S118. Accessed September 16, 2025."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197508)36:2<341::AID-CNCR2820360208>3.0.CO;2-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000206"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01591-4"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.25"},{"key":"e_1_3_3_9_2","first-page":"18","article-title":"Real-world analysis of oral chemotherapy dose modifications during maintenance therapy for young adults with ALL","volume":"14","author":"Shah R","year":"2024","unstructured":"Shah R, Waldron M, Siebenaller C, et al. Real-world analysis of oral chemotherapy dose modifications during maintenance therapy for young adults with ALL. J Hematol Oncol Pharm 2024; 14: 18\u201326.","journal-title":"J Hematol Oncol Pharm"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000512"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.026666"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.17.00039"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.7.3"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221142872"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251324522"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160475"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023568"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8010043"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261421898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261421898","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261421898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:15:21Z","timestamp":1779185721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261421898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":17,"alternative-id":["10.1177\/10781552261421898"],"URL":"https:\/\/doi.org\/10.1177\/10781552261421898","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"10781552261421898"}}